A new drug candidate in the fight against cancer
Press release: SATT Nord and Apmonia Therapeutics have entered into agreements in which Apmonia Therapeutics has been granted an exclusive worldwide license for the development
Press release: SATT Nord and Apmonia Therapeutics have entered into agreements in which Apmonia Therapeutics has been granted an exclusive worldwide license for the development
Apmonia Therapeutics is honored and delighted to have been elected as most promising #startup of the year during “Welcome to Reims” event last week. We
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.